Psychedelics 101 & 102 | New York City

June 20 & 21 at the Open Center, NYC

Get TicketsTickets coming soon!

Event details

Psychedelics 101 & 102

Location:

Open Center

22 E. 30th Street

New York, NY 10016

Date & Time:

10:00 AM- 5PM, June 20 & 21, 2020

Faculty:

Elizabeth Nielson & Ingmar Gorman

Cost:

$450

The scholarship application for this program is now closed. Please click here to see other programs we have scholarships available for.


This 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This interactive training includes role plays, demonstrations, case examples, and experiential learning opportunities. 


This workshop has an enrollment limited to 60 participants. Lead trainers Drs Gorman & Nielson as well as 2 assisting trainers will be present. This workshop has been offered nationally and internationally over 10 times in the last 2 years and has routinely sold out and generated a waiting list. Upon completion, participants will be offered the opportunity to join the presenters’ google group with over 500 past program participants for networking and continued collaboration.


Psychedelics 101: Your patients are curious and so are you: What is all this about psychedelics being used for treatment of addiction and trauma? This session gives an overview of psychedelic drugs, their history, and current research with MDMA and Psilocybin-assisted therapy. This program includes an overview of recent and current clinical trials, outcomes, legal status, and what it all means for the future of addiction and trauma treatment.


Learning Objectives:


  • Discuss the historical justifications for psychedelic clinical research
  • Describe key theoretical approaches to psychedelic-assisted therapy
  • Discuss the state of psychedelic clinical research, rescheduling efforts, and how psychedelic-assisted psychotherapy works with clients
  • Compare psychedelic integration psychotherapy to integration in peer and shamanic settings


Psychedelics 102: This day introduces clinical skills for psychedelic harm reduction and integration work in the clinical setting. This program focuses on translating research findings into clinical practice including working with patients who are considering using psychedelics, actually using psychedelics, or have used them. Includes discussion of assessment and integration techniques, resources, and legal and ethical issues. 


Learning Objectives:

    

  • Assess clients for key “red flags” that indicate someone should seek specialized psychiatric care after a psychedelic experience
  • Utilize principles of psychedelic-assisted therapy in a basic/initial assessment of clients who report psychedelic use
  • List contraindications and discuss high risk cases of individuals who are contemplating psychedelic use
  • Describe the role of the therapist in an individual's integration psychotherapy process